| PU20.02 | Asymptomatic bacterial STI in young men who have sex with men minimally alters rectal mucosal immune cell ecosystem | Publication Only | Mucosal immunity |
| OA08.05LB | Development of a novel VRC01-class germline targeting immunogen derived from anti-idiotypic antibodies | Oral Abstract Session | Novel vaccine and other prevention approaches |
| OA09.01 | BCG.HTI2auxo.int priming vaccination enhances the HIV-1 specific T cell immune responses elicited by MVA.HTI | Oral Abstract Session | Novel vaccine and other prevention approaches |
| OA12.01 | Fine-tuning of in vitro transcribed mRNA for optimising a vaccine platform against HIV-1 | Oral Abstract Session | Novel vaccine and other prevention approaches |
| OA12.02 | Comparison of co-immunization of DNA and protein in the same anatomical sites and in contralateral sites to identify mechanisms of protective immune response | Oral Abstract Session | Novel vaccine and other prevention approaches |
| OA12.03 | Tetravalent immunogen assembled from conserved regions of HIV-1 and delivered as mRNA demonstrates potent preclinical T cell immunogenicity and breadth | Oral Abstract Session | Novel vaccine and other prevention approaches |
| OA12.04LB | A VSV-based HIV-1 vaccine provides protection in macaques against low dose cross-clade SHIVenv_SF162_P3 challenge | Oral Abstract Session | Novel vaccine and other prevention approaches |
| OA12.05 | Improved in vitro expression and in vivo immunogenicity of a candidate MVA-vectored HIV-1 vaccine compared to SAAVI MVA-C | Oral Abstract Session | Novel vaccine and other prevention approaches |
| OA15.01 | Heterologous vaccination with DNA and two different poxvirus vectors, expressing HIV-1 envelope on the surface of Gag virus-like particles, elicit autologous Tier 2 neutralising antibodies | Oral Abstract Session | Novel vaccine and other prevention approaches |
| OA15.02 | In vitro and in vivo analyses of HIV-1 clade C Envelope trimers highlight optimal antigenic profiles of novel HIV-1 Env-based vaccine candidates | Oral Abstract Session | Novel vaccine and other prevention approaches |